Single inhaler triple therapy in COPD – all that glitters is not gold

Monaldi Archives for Chest Disease ◽

10.4081/monaldi.2021.1617 ◽

2021 ◽

Vol 91 (2) ◽

Author(s):

Kartik Deshmukh ◽

Arjun Khanna

Keyword(s):

Lung Function ◽

Triple Therapy ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Exacerbation Frequency ◽

Long Acting ◽

Dear Editor, The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/or improvement of lung function...

Download Full-text

CAPTAIN STUDY: EFFECT OF BASELINE LUNG FUNCTION ON RESPONSE TO TRIPLE THERAPY IN PATIENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID/LONG-ACTING BETA2-AGONIST THERAPY

CHEST Journal ◽

10.1016/j.chest.2020.09.213 ◽

2020 ◽

Vol 158 (4) ◽

pp. A2621-A2625

Author(s):

Robert Nathan ◽

Louis-Philippe Boulet ◽

Huib Kerstjens ◽

Alberto Papi ◽

Ian Pavord ◽

...

Keyword(s):

Lung Function ◽

Triple Therapy ◽

Inhaled Corticosteroid ◽

Agonist Therapy ◽

Long Acting ◽

Download Full-text

Comparative Effectiveness of Long-Acting Beta2-Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ◽

10.1002/phar.1913 ◽

2017 ◽

Vol 37 (4) ◽

pp. 447-455 ◽

Author(s):

Jennifer C. Samp ◽

Min J. Joo ◽

Glen T. Schumock ◽

Gregory S. Calip ◽

A. Simon Pickard ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Comparative Effectiveness ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Muscarinic Antagonist ◽

Long Acting ◽

Download Full-text

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan

International Journal of Chronic Obstructive Pulmonary Disease ◽

10.2147/copd.s179285 ◽

2018 ◽

Vol Volume 13 ◽

pp. 3141-3147

Author(s):

Hideyasu Yamada ◽

Norihito Hida ◽

Nobuyuki Hizawa

Keyword(s):

Lung Function ◽

Muscarinic Antagonist ◽

Copd Patients ◽

Adrenoceptor Agonist ◽

Beta 2 ◽

Download Full-text

Fixed-Dose combination of the inhaled corticosteroid and long-acting beta2-agonist therapy in adults with persistent asthma

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2016.1145659 ◽

2016 ◽

Vol 17 (5) ◽

pp. 631-642 ◽

Author(s):

Hiroshi Chantaphakul ◽

Kiat Ruxrungtham

Keyword(s):

Persistent Asthma ◽

Fixed Dose Combination ◽

Inhaled Corticosteroid ◽

Agonist Therapy ◽

Dose Combination ◽

Long Acting ◽

Download Full-text

Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis

Respirology ◽

10.1111/resp.12603 ◽

2015 ◽

Vol 20 (8) ◽

pp. 1153-1159 ◽

Author(s):

Nobuyuki Horita ◽

Naoki Miyazawa ◽

Koji Tomaru ◽

Miyo Inoue ◽

Takeshi Kaneko

Keyword(s):

Systematic Review ◽

Meta Analysis ◽

Beta Agonist ◽

Inhaled Corticosteroid ◽

Muscarinic Antagonist ◽

Download Full-text

Aclidinium Bromide Added to a Long-Acting B2-Agonist +/- Inhaled Corticosteroid: Effects on Exacerbations, Lung Function, and Symptoms in Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Risk Factors (ASCENT-COPD)

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2451 ◽

2019 ◽

Author(s):

R.A. Wise ◽

K.R. Chapman ◽

B.M. Scirica ◽

D.L. Bhatt ◽

S.Z. Daoud ◽

...

Keyword(s):

Risk Factors ◽

Chronic Obstructive Pulmonary Disease ◽

Cardiovascular Risk ◽

Lung Function ◽

Cardiovascular Risk Factors ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

Aclidinium Bromide ◽

Download Full-text

Cost-Effectiveness of a Single Inhaler Triple Therapy vs a Dual Inhaled Corticosteroid Plus Long-Acting Beta Agonist (ICS/LABA) for Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom (UK)

Value in Health ◽

10.1016/j.jval.2018.04.1590 ◽

2018 ◽

Vol 21 ◽

pp. S234

Author(s):

E Fenwick ◽

AA Martin ◽

M Schroeder ◽

D Vetrini ◽

S Mealing ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

United Kingdom ◽

Cost Effectiveness ◽

Triple Therapy ◽

Beta Agonist ◽

Chronic Obstructive ◽

Inhaled Corticosteroid ◽

Obstructive Pulmonary Disease ◽

The United Kingdom ◽

Download Full-text

Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist

Allergy and Asthma Proceedings ◽

10.2500/aap.2016.37.3968 ◽

2016 ◽

Vol 37 (4) ◽

pp. 302-310 ◽

Author(s):

Jiangtao Lin ◽

Huaping Tang ◽

Ping Chen ◽

Haoyan Wang ◽

Mi-Kyeong Kim ◽

...

Keyword(s):

Low Dose ◽

Safety Evaluation ◽

Efficacy And Safety ◽

Inhaled Corticosteroid ◽

Fluticasone Furoate ◽

Asian Patients ◽

Long Acting ◽

Download Full-text

Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal

Allergy and Asthma Proceedings ◽

10.2500/aap.2012.33.3512 ◽

2012 ◽

Vol 33 (2) ◽

pp. 140-144 ◽

Author(s):

Peter J. Barnes ◽

Gabriele Nicolini ◽

Andrea Bizzi ◽

Monica Spinola ◽

Dave Singh

Keyword(s):

Inhaled Corticosteroid ◽

Clinical Benefits ◽

Long Acting ◽

Download Full-text

Triple therapy with two long acting bronchodilatatorsand inhaled corticosteroid in COPD

Clinical pharmacology and therapy ◽

10.32756/0869-5490-2019-1-50-56 ◽

2019 ◽

Vol 27 (1) ◽

pp. 50-56

Author(s):

М.V. Lebedeva ◽

M.Yu. Brovko ◽

S.V. Moiseev

Keyword(s):

Triple Therapy ◽

Inhaled Corticosteroid ◽

Download Full-text